Identification of molecular targets associated with ethanol toxicity and implications in drug development

Current Pharmaceutical Design

Volumn 16, Issue 11, 2010, Pages 1313-1355

  Wang, Lin Lin ^a   Yang, An Kui ^b,c   He, Shu Ming ^d   Liang, Jun ^e   Zhou, Zhi Wei ^f   Li, Yong ^a   Zhou, Shu Feng ^f  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d Nanfang Medical University   (China)

^e Novagen Biotech Inc   (Australia)

^f RMIT UNIVERSITY   (Australia)

Author keywords

Acamprosate; Biological pathway; Disulfiram; Drug development; Ethanol; Molecular target; Naltrexone; Toxicity

Indexed keywords

ACAMPROSATE; ALCOHOL; ARIPIPRAZOLE; BACLOFEN; BROMOCRIPTINE; BUSPIRONE; CANNABINOID 1 RECEPTOR ANTAGONIST; CARBAMAZEPINE; CHEMOKINE; CYTOKINE; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOXETINE; INTEGRIN; KEMSTRO; NALTREXONE; ONDANSETRON; PHENYTOIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; QUETIAPINE; RITANSERIN; TOPIRAMATE; UNCLASSIFIED DRUG; WNT PROTEIN;

ALCOHOL ABSTINENCE; ALCOHOL INTOXICATION; ALCOHOL METABOLISM; ALCOHOL RESPONSIVE GENE; ALCOHOLISM; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; APOPTOSIS; ARTICLE; DIARRHEA; DOWN REGULATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GLOSSOPHARYNGEAL NEURALGIA; HUMAN; INFLAMMATION; LIVER INJURY; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NONHUMAN; NUCLEOTIDE SEQUENCE; OPIATE ADDICTION; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; SKIN TOXICITY; SPASTICITY; SYSTEMATIC REVIEW; TRIGEMINUS NEURALGIA; UNINDEXED SEQUENCE; UPREGULATION;

EID: 77950886802     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791034030     Document Type: Article

References (290)

1. Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health 2006; 29: 245-254.
2. Holford NH. Clinical pharmacokinetics of ethanol. Clin Pharmacokinet 1987; 13: 273-292.
3. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007; 7: 599-612.
4. Bradford BU, Enomoto N, Ikejima K, Rose ML, Bojes HK, Forman DT, et al. Peroxisomes are involved in the swift increase in alcohol metabolism. J Pharmacol Exp Ther 1999; 288: 254-259.
5. Guidot DM, Hart CM. Alcohol abuse and acute lung injury: epidemiology and pathophysiology of a recently recognized association. J Investig Med 2005; 53: 235-245.
6. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santolaria- Fernandez F, De La Vega-Prieto MJ, Milena-Abril A, Sanchez- Perez MJ, et al. Brain atrophy in alcoholics: relationship with alcohol intake; liver disease; nutritional status, and inflammation. Alcohol Alcohol 2007; 42: 533-538.
7. Seitz HK, Stickel F. Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol metabolism. Genes Nutr 2009; [Epub ahead of print].
8. Dick DM, Foroud T. Candidate genes for alcohol dependence: a review of genetic evidence from human studies. Alcohol Clin Exp Res 2003; 27: 868-879.
9. McGue M, Slutske W, Iacono WG. Personality and substance use disorders: II. Alcoholism versus drug use disorders. J Consult Clin Psychol 1999; 67: 394-404.
10. Wentzel P, Eriksson UJ. Altered gene expression in neural crest cells exposed to ethanol in vitro. Brain Res 2009; 1305 (Suppl): S50-60.
11. Liu J, Lewohl JM, Harris RA, Dodd PR, Mayfield RD. Altered gene expression profiles in the frontal cortex of cirrhotic alcoholics. Alcohol Clin Exp Res 2007; 31: 1460-1466. (Pubitemid 47319652)
12. Worst TJ, Vrana KE. Alcohol and gene expression in the central nervous system. Alcohol Alcohol 2005; 40: 63-75.
13. Bowers BJ, Radcliffe RA, Smith AM, Miyamoto-Ditmon J, Wehner JM. Microarray analysis identifies cerebellar genes sensitive to chronic ethanol treatment in PKC mice. Alcohol 2006; 40: 19-33. (Pubitemid 44854403)
14. Yin HQ, Kim M, Kim JH, Kong G, Kang KS, Kim HL, et al. Differential gene expression and lipid metabolism in fatty liver induced by acute ethanol treatment in mice. Toxicol Appl Pharmacol 2007; 223: 225-233. (Pubitemid 47371140)
15. Park SH, Choi MS, Park T. Changes in the hepatic gene expression profile in a rat model of chronic ethanol treatment. Food Chem Toxicol 2008; 46: 1378-1388. (Pubitemid 351258198)
16. Mayfield RD, Lewohl JM, Dodd PR, Herlihy A, Liu J, Harris RA. Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics. J Neurochem 2002; 81: 802-813. (Pubitemid 34809308)
17. Sokolov BP, Jiang L, Trivedi NS, Aston C. Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. J Neurosci Res 2003; 72: 756-767. (Pubitemid 36666269)
18. Seth D, Gorrell MD, Cordoba S, McCaughan GW, Haber PS. Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol 2006; 45: 306-320.
19. Asano K, Clayton J, Shalev A, Hinnebusch AG. A multifactor complex of eukaryotic initiation factors, eIF1, eIF2, eIF3, eIF5, and initiator tRNA(Met) is an important translation initiation intermediate in vivo. Genes Dev 2000; 14: 2534-2546.
20. Vary TC, Deiter G, Goodman SA. Acute alcohol intoxication enhances myocardial eIF4G phosphorylation despite reducing mTOR signaling. Am J Physiol Heart Circ Physiol 2005; 288: H121-8. (Pubitemid 40023838)
21. Lang CH, Wu D, Frost RA, Jefferson LS, Vary TC, Kimball SR. Chronic alcohol feeding impairs hepatic translation initiation by modulating eIF2 and eIF4E. Am J Physiol 1999; 277: E805-14.
22. Vary TC, Kimball SR, Sumner A. Sex-dependent differences in the regulation of myocardial protein synthesis following long-term ethanol consumption. Am J Physiol Regul Integr Comp Physiol 2007; 292: R778-87. (Pubitemid 46207730)
23. Edenberg HJ, Xuei X, Wetherill LF, Bierut L, Bucholz K, Dick DM, et al. Association of NFKB1, which encodes a subunit of the transcription factor NF-κB, with alcohol dependence. Hum Mol Genet 2008; 17: 963-970.
24. Ronis MJ, Butura A, Korourian S, Shankar K, Simpson P, Badeaux J, et al. Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. Exp Biol Med (Maywood) 2008; 233: 344-355.
25. Venugopal SK, Chen J, Zhang Y, Clemens D, Follenzi A, Zern MA. Role of MAPK phosphatase-1 in sustained activation of JNK during ethanol-induced apoptosis in hepatocyte-like VL-17A cells. J Biol Chem 2007; 282: 31900-31908.
26. Goral J, Choudhry MA, Kovacs EJ. Acute ethanol exposure inhibits macrophage IL-6 production: role of p38 and ERK1/2 MAPK. J Leukoc Biol 2004; 75: 553-559.
27. Lee YJ, Shukla SD. Histone H3 phosphorylation at serine 10 and serine 28 is mediated by p38 MAPK in rat hepatocytes exposed to ethanol and acetaldehyde. Eur J Pharmacol 2007; 573: 29-38.
28. Tsuji R, Guizzetti M, Costa LG. In vivo ethanol decreases phosphorylated MAPK and p70S6 kinase in the developing rat brain. Neuroreport 2003; 14: 1395-1399.
29. Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, et al. International Union of Pharmacology. XV. Subtypes of γ-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998; 50: 291-313.
30. Volgin DV. Perinatal alcohol exposure leads to prolonged upregulation of hypothalamic GABAA receptors and increases behavioral sensitivity to gaboxadol. Neurosci Lett 2008; 439: 182-186.
31. Soyka M, Preuss UW, Hesselbrock V, Zill P, Koller G, Bondy B. GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. J Psychiatr Res 2008; 42: 184-191.
32. Reich T. A genomic survey of alcohol dependence and related phenotypes: results from the Collaborative Study on the Genetics of Alcoholism (COGA). Alcohol Clin Exp Res 1996; 20: 133A-7A. (Pubitemid 26393978)
33. Reich T, Edenberg HJ, Goate A, Williams JT, Rice JP, Van Eerdewegh P, et al. Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet 1998; 81: 207-215. (Pubitemid 28211180)
34. Dick DM, Edenberg HJ, Xuei X, Goate A, Kuperman S, Schuckit M, et al. Association of GABRG3 with alcohol dependence. Alcohol Clin Exp Res 2004; 28: 4-9.
35. Wallner M, Hanchar HJ, Olsen RW. Low dose acute alcohol effects on GABA A receptor subtypes. Pharmacol Ther 2006; 112: 513-528. (Pubitemid 44488711)
36. Lobo IA, Harris RA. GABAA receptors and alcohol. Pharmacol Biochem Behav 2008; 90: 90-94.
37. Koob GF. A role for GABA mechanisms in the motivational effects of alcohol. Biochem Pharmacol 2004; 68: 1515-1525.
38. Rojdmark S, Rydvald Y, Aquilonius A, Brismar K. Insulin-like growth factor (IGF)-1 and IGF-binding protein-1 concentrations in serum of normal subjects after alcohol ingestion: evidence for decreased IGF-1 bioavailability. Clin Endocrinol (Oxf) 2000; 52: 313-318.
39. Lang CH, Frost RA, Svanberg E, Vary TC. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. Am J Physiol Endocrinol Metab 2004; 286: E916-26. (Pubitemid 38668813)
40. Lee SM, Alam R, Ho CJ, Kim JH, Kang CW, Park JH, et al. Involvement of p42/44 MAPK in the effects of ethanol on secretion of insulin-like growth factor (IGF)-I and insulin-like growth factor binding protein (IGFBP)-1 in primary cultured rat hepatocytes. Int J Neurosci 2007; 117: 187-201. (Pubitemid 46256494)
41. Lian F, Chung J, Russell RM, Wang XD. Alcohol-reduced plasma IGF-I levels and hepatic IGF-I expression can be partially restored by retinoic acid supplementation in rats. J Nutr 2004; 134: 2953-2956. (Pubitemid 39470068)
42. Lee MS, Kim MS, Park SY, Kang CW. Effects of betaine on ethanol-stimulated secretion of IGF-I and IGFBP-1 in rat primary hepatocytes: involvement of p42/44 MAPK activation. World J Gastroenterol 2006; 12: 1718-1722.
43. Bertrand J, Floyd LL, Weber MK. Guidelines for identifying and referring persons with fetal alcohol syndrome. MMWR Recomm Rep 2005; 54: 1-14.
44. Jones MK, Itani RM, Wang H, Tomikawa M, Sarfeh IJ, Szabo S, et al. Activation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injury. Am J Physiol 1999; 276: G1345-55.
45. Castaneda F, Rosin-Steiner S, Jung K. Functional genomics analysis of low concentration of ethanol in human hepatocellular carcinoma (HepG2) cells. Role of genes involved in transcriptional and translational processes. Int J Med Sci 2007; 4: 28-35. (Pubitemid 46294009)
46. Bora PS, Kaliappan S, Xu Q, Kumar S, Wang Y, Kaplan HJ, et al. Alcohol linked to enhanced angiogenesis in rat model of choroidal neovascularization. FEBS J 2006; 273: 1403-1414. (Pubitemid 44029106)
47. Radek KA, Matthies AM, Burns AL, Heinrich SA, Kovacs EJ, Dipietro LA. Acute ethanol exposure impairs angiogenesis and the proliferative phase of wound healing. Am J Physiol Heart Circ Physiol 2005; 289: H1084-90.
48. Qian Y, Luo J, Leonard SS, Harris GK, Millecchia L, Flynn DC, et al. Hydrogen peroxide formation and actin filament reorganization by Cdc42 are essential for ethanol-induced in vitro angiogenesis. J Biol Chem 2003; 278: 16189-16197. (Pubitemid 36799742)
49. Qian Y, Luo J, Leonard SS, Harris GK, Millecchia L, Flynn DC, et al. Hydrogen peroxide formation and actin filament reorganization by Cdc42 are essential for ethanol-induced in vitro angiogenesis. Nihon Arukoru Yakubutsu Igakkai Zasshi 2007; 42: 605-609.
50. Szabo IL, Kawanaka H, Jones MK, Pai R, Soreghan BA, Baatar D, et al. Activation of hypoxia inducible factor-1α in gastric mucosa in response to ethanol injury: a trigger for angiogenesis? Life Sci 2001; 69: 3035-3044.
51. Jones MK, Sarfeh IJ, Tarnawski AS. Induction of in vitro angiogenesis in the endothelial-derived cell line, EA hy926, by ethanol is mediated through PKC and MAPK. Biochem Biophys Res Commun 1998; 249: 118-123.
52. Gu JW, Elam J, Sartin A, Li W, Roach R, Adair TH. Moderate levels of ethanol induce expression of vascular endothelial growth factor and stimulate angiogenesis. Am J Physiol Regul Integr Comp Physiol 2001; 281: R365-72. (Pubitemid 32911865)
53. Luo J, Miller MW. Growth factor-mediated neural proliferation: target of ethanol toxicity. Brain Res Brain Res Rev 1998; 27: 157-167. (Pubitemid 28308040)
54. Brancaleoni GH, Lourenzoni MR, Degreve L. Study of the influence of ethanol on basic fibroblast growth factor structure. Genet Mol Res 2006; 5: 350-372. (Pubitemid 43991974)
55. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268: 233-239.
56. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995; 11: 549-599.
57. Huveneers S, Truong H, Danen HJ. Integrins: signaling, disease, and therapy. Int J Radiat Biol 2007; 83: 743-751.
58. Ingber DE. Tensegrity: the architectural basis of cellular mechanotransduction. Annu Rev Physiol 1997; 59: 575-599.
59. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
60. Giancotti FG. Integrin signaling: specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol 1997; 9: 691-700. (Pubitemid 27424926)
61. Lee TC, Chow KL, Fang P, Schwartz RJ. Activation of skeletal alpha-actin gene transcription: the cooperative formation of serum response factor-binding complexes over positive cis-acting promoter serum response elements displaces a negative-acting nuclear factor enriched in replicating myoblasts and nonmyogenic cells. Mol Cell Biol 1991; 11: 5090-5100.
62. Farkas A, Kemeny L, Szell M, Dobozy A, Bata-Csorgo Z. Ethanol and acetone stimulate the proliferation of HaCaT keratinocytes: the possible role of alcohol in exacerbating psoriasis. Arch Dermatol Res 2003; 295: 56-62.
63. Rout UK. Valproate, thalidomide and ethyl alcohol alter the migration of HTR-8/SVneo cells. Reprod Biol Endocrinol 2006; 4: 44.
64. Mussig E, Steinberg T, Kohl A, Chamulitrat W, Komposch G, Tomakidi P. Discrimination of epithelium-like and fibroblast-like phenotypes derived from ethanol-treated immortalised human gingival keratinocytes in epithelial equivalents. Cell Tissue Res 2008; 332: 57-71.
65. Tuma DJ, Smith TE, Schaffert CS, Kharbanda KK, Sorrell MF. Ethanol feeding selectively impairs the spreading of rat perivenous hepatocytes on extracellular matrix substrates. Alcohol Clin Exp Res 1999; 23: 1673-1680.
66. Schaffert CS, Sorrell MF, Tuma DJ. Expression and cytoskeletal association of integrin subunits is selectively increased in rat perivenous hepatocytes after chronic ethanol administration. Alcohol Clin Exp Res 2001; 25: 1749-1757.
67. Sacanella E, Estruch R, Gaya A, Ferrer K, Fernandez-Sola J, Alonso JR, et al. Upregulated expression of VLA proteins and CD29 in peripheral blood lymphocytes of chronic alcoholics without ethanol-related diseases. Alcohol Clin Exp Res 1999; 23: 371-375.
68. Zhang P, Bagby GJ, Xie M, Stoltz DA, Summer WR, Nelson S. Acute ethanol intoxication inhibits neutrophil β2-integrin expression in rats during endotoxemia. Alcohol Clin Exp Res 1998; 22: 135-141.
69. Vangipuram SD, Grever WE, Parker GC, Lyman WD. Ethanol increases fetal human neurosphere size and alters adhesion molecule gene expression. Alcohol Clin Exp Res 2008; 32: 339-347.
70. Ozaki M, Ogata M, Nandate K, Kawasaki T, Sata T. The effects of ethanol on β2-integrin and L-selectin on the surface of leukocytes in human whole blood. J Trauma 2007; 63: 770-774.
71. Siegenthaler JA, Miller MW. Transforming growth factor beta1 modulates cell migration in rat cortex: effects of ethanol. Cereb Cortex 2004; 14: 791-802.
72. Burridge K, Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 1996; 12: 463-518.
73. Carson JA, Wei L. Integrin signaling's potential for mediating gene expression in hypertrophying skeletal muscle. J Appl Physiol 2000; 88: 337-343.
74. Paulhe F, Manenti S, Ysebaert L, Betous R, Sultan P, Racaud- Sultan C. Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancer. Curr Pharm Des 2005; 11: 2119-2134.
75. Gullberg D, Velling T, Lohikangas L, Tiger CF. Integrins during muscle development and in muscular dystrophies. Front Biosci 1998; 3: D1039-50.
76. Parise LV, Lee J, Juliano RL. New aspects of integrin signaling in cancer. Semin Cancer Biol 2000; 10: 407-414.
77. Cheresh DA, Leng J, Klemke RL. Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol 1999; 146: 1107-1116.
78. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999; 146: 389-403.
79. Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999; 144: 1235-1244.
80. Kulkarni SV, Gish G, van der Geer P, Henkemeyer M, Pawson T. Role of p120 Ras-GAP in directed cell movement. J Cell Biol 2000; 149: 457-470. (Pubitemid 30227161)
81. Znoyko I, Trojanowska M, Reuben A. Collagen binding alpha2beta1 and alpha1beta1 integrins play contrasting roles in regulation of Ets-1 expression in human liver myofibroblasts. Mol Cell Biochem 2006; 282: 89-99.
82. Gullberg DE, Lundgren-Akerlund E. Collagen-binding I domain integrins what do they do? Prog Histochem Cytochem 2002; 37: 3-54.
83. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a β1 integrin viability signaling pathway. J Biol Chem 2004; 279: 33024-33034.
84. Muckian C, Fitzgerald A, O'Neill A, O'Byrne A, Fitzgerald DJ, Shields DC. Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. Blood 2002; 100: 1220-1223.
85. Schaffert CS, Todero SL, Casey CA, Thiele GM, Sorrell MF, Tuma DJ. Chronic ethanol treatment impairs Rac and Cdc42 activation in rat hepatocytes. Alcohol Clin Exp Res 2006; 30: 1208-1213.
86. Klei LR, Barchowsky A. Positive signaling interactions between arsenic and ethanol for angiogenic gene induction in human microvascular endothelial cells. Toxicol Sci 2008; 102: 319-327. (Pubitemid 351404902)
87. Hines IN, Wheeler MD. Recent advances in alcoholic liver disease III. Role of the innate immune response in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2004; 287: G310-4.
88. Jerrells TR, Vidlak D, Strachota JM. Alcoholic pancreatitis: mechanisms of viral infections as cofactors in the development of acute and chronic pancreatitis and fibrosis. J Leukoc Biol 2007; 81: 430-439. (Pubitemid 46198394)
89. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13: 267-276.
90. McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993; 13: 170-182.
91. Boe DM, Nelson S, Zhang P, Quinton L, Bagby GJ. Alcoholinduced suppression of lung chemokine production and the host defense response to Streptococcus pneumoniae. Alcohol Clin Exp Res 2003; 27: 1838-1845.
92. Szabo G, Mandrekar P, Girouard L, Catalano D. Regulation of human monocyte functions by acute ethanol treatment: decreased tumor necrosis factor-β, interleukin-1 beta and elevated interleukin-10, and transforming growth factor-β production. Alcohol Clin Exp Res 1996; 20: 900-907.
93. Goral J, Kovacs EJ. In vivo ethanol exposure down-regulates TLR2-, TLR4-, and TLR9-mediated macrophage inflammatory response by limiting p38 and ERK1/2 activation. J Immunol 2005; 174: 456-463.
94. Averina M, Nilssen O, Arkhipovsky VL, Kalinin AG, Brox J. Creactive protein and alcohol consumption: Is there a U-shaped association? Results from a population-based study in Russia. The Arkhangelsk study. Atherosclerosis 2006; 188: 309-315.
95. Hijmering ML, de Lange DW, Lorsheyd A, Kraaijenhagen RJ, van de Wiel A. Binge drinking causes endothelial dysfunction, which is not prevented by wine polyphenols: a small trial in healthy volunteers. Neth J Med 2007; 65: 29-35.
96. Szabo G, Mandrekar P, Dolganiuc A, Catalano D, Kodys K. Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFN levels. Alcohol Clin Exp Res 2001; 25: 1766-1772.
97. Saeed RW, Varma S, Peng T, Tracey KJ, Sherry B, Metz CN. Ethanol blocks leukocyte recruitment and endothelial cell activation in vivo and in vitro. J Immunol 2004; 173: 6376-6383.
98. McEwen DG, Peifer M. Wnt signaling: moving in a new direction. Curr Biol 2000; 10: R562-4.
99. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004; 341: 19-39.
100. Yeh CH, Chang JK, Wang YH, Ho ML, Wang GJ. Ethanol may suppress Wnt/β-catenin signaling on human bone marrow stroma cells: a preliminary study. Clin Orthop Relat Res 2008; 466: 1047-1053.
101. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107: 513-523. (Pubitemid 33152786)
102. Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 2005; 102: 17406-17411. (Pubitemid 41740879)
103. Luo J, Miller MW. Differential sensitivity of human neuroblastoma cell lines to ethanol: correlations with their proliferative responses to mitogenic growth factors and expression of growth factor receptors. Alcohol Clin Exp Res 1997; 21: 1186-1194. (Pubitemid 27446884)
104. Luo J, Miller MW. Platelet-derived growth factor-mediated signal transduction underlying astrocyte proliferation: site of ethanol action. J Neurosci 1999; 19: 10014-10025. (Pubitemid 30226673)
105. Luo J, Miller MW. Basic fibroblast growth factor- and plateletderived growth factor-mediated cell proliferation in B104 neuroblastoma cells: effect of ethanol on cell cycle kinetics. Brain Res 1997; 770: 139-150. (Pubitemid 27468061)
106. Wang J, Gutala R, Sun D, Ma JZ, Sheela RC, Ticku MK, et al. Regulation of platelet-derived growth factor signaling pathway by ethanol, nicotine, or both in mouse cortical neurons. Alcohol Clin Exp Res 2007; 31: 357-375. (Pubitemid 46239267)
107. Pritchard MT, Nagy LE. Ethanol-induced liver injury: potential roles for egr-1. Alcohol Clin Exp Res 2005; 29: 146S-50S.
108. Hu R, Wang YL, Edderkaoui M, Lugea A, Apte MV, Pandol SJ. Ethanol augments PDGF-induced NADPH oxidase activity and proliferation in rat pancreatic stellate cells. Pancreatology 2007; 7: 332-340.
109. Yeo EJ, Lim HK, Park SC. Effect of short-term ethanol on the proliferative response of Swiss 3T3 cells to mitogenic growth factors. Exp Mol Med 2000; 32: 161-169.
110. Kornfehl J, Temmel A, Formanek M, Knerer B. Effects of ethanol treatment of proliferation and differentiation in a head and neck squamous cell carcinoma cell line. Alcohol Clin Exp Res 1999; 23: 1102-1107.
111. Levine AJ, Hu W, Feng Z. The p53 pathway: what questions remain to be explored? Cell Death Differ 2006; 13: 1027-1036.
112. Lee RD, An SM, Kim SS, Rhee GS, Kwack SJ, Seok JH, et al. Neurotoxic effects of alcohol and acetaldehyde during embryonic development. J Toxicol Environ Health A 2005; 68: 2147-2162.
113. Jankala H, Eriksson PC, Eklund K, Sarviharju M, Harkonen M, Maki T. Effect of chronic ethanol ingestion and gender on heart left ventricular p53 gene expression. Alcohol Clin Exp Res 2005; 29: 1368-1373.
114. Meng XF, Zou XJ, Peng B, Shi J, Guan XM, Zhang C. Inhibition of ethanol-induced toxicity by tanshinone IIA in PC12 cells. Acta Pharmacol Sin 2006; 27: 659-664.
115. Nowoslawski L, Klocke BJ, Roth KA. Molecular regulation of acute ethanol-induced neuron apoptosis. J Neuropathol Exp Neurol 2005; 64: 490-497.
116. Pani G, Fusco S, Colavitti R, Borrello S, Maggiano N, Cravero AA, et al. Abrogation of hepatocyte apoptosis and early appearance of liver dysplasia in ethanol-fed p53-deficient mice. Biochem Biophys Res Commun 2004; 325: 97-100.
117. Freudenheim JL, Bonner M, Krishnan S, Ambrosone CB, Graham S, McCann SE, et al. Diet and alcohol consumption in relation to p53 mutations in breast tumors. Carcinogenesis 2004; 25: 931-939.
118. Terry MB, Neugut AI, Mansukhani M, Waye J, Harpaz N, Hibshoosh H. Tobacco, alcohol, and p53 overexpression in early colorectal neoplasia. BMC Cancer 2003; 3: 29.
119. Saeki H, Ohno S, Araki K, Egashira A, Kawaguchi H, Ikeda Y, et al. Alcohol consumption and cigarette smoking in relation to high frequency of p53 protein accumulation in oesophageal squamous cell carcinoma in the Japanese. Br J Cancer 2000; 82: 1892-1894.
120. Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 2000; 60: 3155-3159.
121. Miyazaki M, Ohno S, Futatsugi M, Saeki H, Ohga T, Watanabe M. The relation of alcohol consumption and cigarette smoking to the multiple occurrence of esophageal dysplasia and squamous cell carcinoma. Surgery 2002; 131: S7-S13.
122. Badgwell DB, Walker CM, Baker WT, Strickland FM. Ethanol and aloe emodin alter the p53 mutational spectrum in ultraviolet radiation-induced murine skin tumors. Mol Carcinog 2004; 39: 127-138.
123. Choi SW, Stickel F, Baik HW, Kim YI, Seitz HK, Mason JB. Chronic alcohol consumption induces genomic but not p53-specific DNA hypomethylation in rat colon. J Nutr 1999; 129: 1945-1950.
124. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-26.
125. Fallon JH, Seroogy KB, Loughlin SE, Morrison RS, Bradshaw RA, Knaver DJ, et al. Epidermal growth factor immunoreactive material in the central nervous system: location and development. Science 1984; 224: 1107-1109.
126. Koken T, Erkasap N, Serteser M, Kahraman A. Epidermal growth factor increases tissue antioxidant enzyme activities in ethanolinduced gastric injury in rat. J Physiol Biochem 2006; 62: 237-243.
127. Erkasap S, Erkasap N, Aral E, Koken T, Kahraman A, Aydin Y, et al. Mast cell stabilizator and antioxidant effects of epidermal growth factor (EGF) on gastric mucosal injury induced by ethanol in rats. Chin J Physiol 2005; 48: 1-6.
128. Sant'Anna LB, Tosello DO, Pasetto S. Effects of maternal ethanol intake on immunoexpression of epidermal growth factor in developing rat mandibular molar. Arch Oral Biol 2005; 50: 625-634.
129. Jimenez-Farfan D, Guevara J, Zenteno E, Malagon H, Hernandez- Guerrero JC. EGF-R and erbB-2 in murine tooth development after ethanol exposure. Birth Defects Res A Clin Mol Teratol 2005; 73: 65-71. (Pubitemid 40289530)
130. Banan A, Choudhary S, Zhang Y, Fields JZ, Keshavarzian A. Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. J Pharmacol Exp Ther 1999; 291: 1075-1085.
131. Turan Akay M, Arzu Kockaya E. The effects of alcohol on rat placenta. Cell Biochem Funct 2005; 23: 435-445.
132. Deaciuc IV, D'Souza NB, Burikhanov R, Lee EY, Tarba CN, McClain CJ, et al. Epidermal growth factor protects the liver against alcohol-induced injury and sensitization to bacterial lipopolysaccharide. Alcohol Clin Exp Res 2002; 26: 864-874. (Pubitemid 34666147)
133. Ma C, Bower KA, Lin H, Chen G, Huang C, Shi X, et al. The role of epidermal growth factor receptor in ethanol-mediated inhibition of activator protein-1 transactivation. Biochem Pharmacol 2005; 69: 1785-1794. (Pubitemid 40780078)
134. Washington B, Mtshali C, Williams S, Smith H, Li JD, Shaw B, et al. Ethanol-induced mitogen activated protein kinase activity mediated through protein kinase C. Cell Mol Biol (Noisy-le-grand) 2003; 49: 1351-1356.
135. Zhang BH, Ho V, Farrell GC. Specific involvement of G i2 with epidermal growth factor receptor signaling in rat hepatocytes, and the inhibitory effect of chronic ethanol. Biochem Pharmacol 2001; 61: 1021-1027. (Pubitemid 32247390)
136. Tong WM, Manhardt T, Lassnig H, Cross HS. Induction of epidermal growth factor receptor expression and mitogenesis by alcohol in human colon adenocarcinoma-derived Caco-2 cells. Anticancer Res 1999; 19: 3321-3325. (Pubitemid 30042626)
137. Zhang BH, Farrell GC. Chronic ethanol consumption disrupts complexation between EGF receptor and phospholipase C- 1: relevance to impaired hepatocyte proliferation. Biochem Biophys Res Commun 1999; 257: 89-94.
138. Vuorela P, Sarkola T, Alfthan H, Halmesmaki E. Hepatocyte growth factor, epidermal growth factor, and placenta growth factor concentrations in peripheral blood of pregnant women with alcohol abuse. Alcohol Clin Exp Res 2002; 26: 682-687. (Pubitemid 34522676)
139. Hiney JK, Dearth RK, Srivastava V, Rettori V, Dees WL. Actions of ethanol on epidermal growth factor receptor activated luteinizing hormone secretion. J Stud Alcohol 2003; 64: 809-816. (Pubitemid 38018427)
140. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
141. Siler-Marsiglio KI, Paiva M, Madorsky I, Pan Q, Shaw G, Heaton MB. Functional mechanisms of apoptosis-related proteins in neonatal rat cerebellum are differentially influenced by ethanol at postnatal days 4 and 7. J Neurosci Res 2005; 81: 632-643. (Pubitemid 41532159)
142. Guan Z, Lui CY, Morkin E, Bahl JJ. Oxidative stress and apoptosis in cardiomyocyte induced by high-dose alcohol. J Cardiovasc Pharmacol 2004; 44: 696-702. (Pubitemid 39587432)
143. Kilburn BA, Chiang PJ, Wang J, Flentke GR, Smith SM, Armant DR. Rapid induction of apoptosis in gastrulating mouse embryos by ethanol and its prevention by HB-EGF. Alcohol Clin Exp Res 2006; 30: 127-134. (Pubitemid 43341405)
144. Neuman MG, Haber JA, Malkiewicz IM, Cameron RG, Katz GG, Shear NH. Ethanol signals for apoptosis in cultured skin cells. Alcohol 2002; 26: 179-190. (Pubitemid 34626312)
145. Tenkova T, Young C, Dikranian K, Labruyere J, Olney JW. Ethanol-induced apoptosis in the developing visual system during synaptogenesis. Invest Ophthalmol Vis Sci 2003; 44: 2809-2817. (Pubitemid 36759739)
146. Brown LA, Harris FL, Guidot DM. Chronic ethanol ingestion potentiates TNF-α-mediated oxidative stress and apoptosis in rat type II cells. Am J Physiol Lung Cell Mol Physiol 2001; 281: L377-86.
147. Higuchi H, Kurose I, Kato S, Miura S, Ishii H. Ethanol-induced apoptosis and oxidative stress in hepatocytes. Alcohol Clin Exp Res 1996; 20: 340A-6A. (Pubitemid 27009763)
148. Robin MA, Demeilliers C, Sutton A, Paradis V, Maisonneuve C, Dubois S, et al. Alcohol increases tumor necrosis factor alpha and decreases nuclear factor-κb to activate hepatic apoptosis in genetically obese mice. Hepatology 2005; 42: 1280-1290.
149. Moulin M, Carpentier S, Levade T, Arrigo AP. Potential roles of membrane fluidity and ceramide in hyperthermia and alcohol stimulation of TRAIL apoptosis. Apoptosis 2007; 12: 1703-1720.
150. Casey CA, Lee SM, Aziz-Seible R, McVicker BL. Impaired receptor-mediated endocytosis: its role in alcohol-induced apoptosis. J Gastroenterol Hepatol 2008; 23 (Suppl 1): S46-9.
151. Krzyzanski W, Oberdoester J, Rabin RA. Mechanism of ethanol enhancement of apoptosis and caspase activation in serum-deprived PC12 cells. Life Sci 2007; 81: 756-764.
152. Garic-Stankovic A, Hernandez MR, Chiang PJ, Debelak-Kragtorp KA, Flentke GR, Armant DR, et al. Ethanol triggers neural crest apoptosis through the selective activation of a pertussis toxinsensitive G protein and a phospholipase Cβ-dependent Ca2+ transient. Alcohol Clin Exp Res 2005; 29: 1237-1246.
153. Corrao G, Bagnardi V, Zambon A, Torchio P. Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol Alcohol 1998; 33: 381-392.
154. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7: 149-156.
155. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 2006; 41: 209-224.
156. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004; 38: 613-619.
157. Ragonese P, Salemi G, Morgante L, Aridon P, Epifanio A, Buffa D, et al. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. Neuroepidemiology 2003; 22: 297-304.
158. Poikolainen K. It can be bad for the heart, too drinking patterns and coronary heart disease. Addiction 1998; 93: 1757-1759.
159. Bagnardi V, Zatonski W, Scotti L, La Vecchia C, Corrao G. Does drinking pattern modify the effect of alcohol on the risk of coronary heart disease? Evidence from a meta-analysis. J Epidemiol Community Health 2008; 62: 615-619.
160. Bevan RJ, Slack RJ, Holmes P, Levy LS. An assessment of potential cancer risk following occupational exposure to ethanol. J Toxicol Environ Health B Crit Rev 2009; 12: 188-205.
161. Rohrmann S, Linseisen J, Vrieling A, Boffetta P, Stolzenberg- Solomon RZ, Lowenfels AB, et al. Ethanol intake and the risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2009; 20: 785-794.
162. Salaspuro MP. Acetaldehyde, microbes, and cancer of the digestive tract. Crit Rev Clin Lab Sci 2003; 40: 183-208.
163. Seitz HK, Matsuzaki S, Yokoyama A, Homann N, Vakevainen S, Wang XD. Alcohol and cancer. Alcohol Clin Exp Res 2001; 25: 137S-43S.
164. Hiraki A, Matsuo K, Wakai K, Suzuki T, Hasegawa Y, Tajima K. Gene-gene and gene-environment interactions between alcohol drinking habit and polymorphisms in alcohol-metabolizing enzyme genes and the risk of head and neck cancer in Japan. Cancer Sci 2007; 98: 1087-1091.
165. Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, et al. Gene-environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis 2001; 22: 913-916.
166. Murata M, Tagawa M, Watanabe S, Kimura H, Takeshita T, Morimoto K. Genotype difference of aldehyde dehydrogenase 2 gene in alcohol drinkers influences the incidence of Japanese colorectal cancer patients. Jpn J Cancer Res 1999; 90: 711-719.
167. Zavras AI, Wu T, Laskaris G, Wang YF, Cartsos V, Segas J, et al. Interaction between a single nucleotide polymorphism in the alcohol dehydrogenase 3 gene, alcohol consumption and oral cancer risk. Int J Cancer 2002; 97: 526-530.
168. Yang CX, Matsuo K, Ito H, Shinoda M, Hatooka S, Hirose K, et al. Gene-environment interactions between alcohol drinking and the MTHFR C677T polymorphism impact on esophageal cancer risk: results of a case-control study in Japan. Carcinogenesis 2005; 26: 1285-1290.
169. Hong YC, Lee KH, Kim WC, Choi SK, Woo ZH, Shin SK, et al. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int J Cancer 2005; 116: 428-432.
170. Bongaerts BW, de Goeij AF, van den Brandt PA, Weijenberg MP. Alcohol and the risk of colon and rectal cancer with mutations in the K-ras gene. Alcohol 2006; 38: 147-154. (Pubitemid 44189160)
171. Caceres DD, Iturrieta J, Acevedo C, Huidobro C, Varela N, Quinones L. Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: exploring some gene-gene and gene-environment interactions. Eur J Epidemiol 2005; 20: 79-88. (Pubitemid 40202687)
172. Bosron WF, Li TK. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology 1986; 6: 502-510.
173. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, et al. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 1992; 88: 344-346.
174. Higuchi S, Matsushita S, Murayama M, Takagi S, Hayashida M. Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Am J Psychiatry 1995; 152: 1219-1221.
175. Yokoyama A, Muramatsu T, Omori T, Matsushita S, Yoshimizu H, Higuchi S, et al. Alcohol and aldehyde dehydrogenase gene polymorphisms influence susceptibility to esophageal cancer in Japanese alcoholics. Alcohol Clin Exp Res 1999; 23: 1705-1710.
176. Yokoyama A, Muramatsu T, Omori T, Yokoyama T, Matsushita S, Higuchi S, et al. Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. Carcinogenesis 2001; 22: 433-439. (Pubitemid 32203822)
177. Crabb DW, Edenberg HJ, Bosron WF, Li TK. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH22 allele is dominant. J Clin Invest 1989; 83: 314-316.
178. Takeshita T, Morimoto K, Mao X, Hashimoto T, Furuyama J. Characterization of the three genotypes of low Km aldehyde dehydrogenase in a Japanese population. Hum Genet 1994; 94: 217-223.
179. Matsuo K, Ito H, Wakai K, Hirose K, Saito T, Suzuki T, et al. Onecarbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. Carcinogenesis 2005; 26: 2164-2171.
180. Yang CX, Matsuo K, Ito H, Hirose K, Wakai K, Saito T, et al. Esophageal cancer risk by ALDH2 and ADH2 polymorphisms and alcohol consumption: exploration of gene-environment and genegene interactions. Asian Pac J Cancer Prev 2005; 6: 256-262.
181. Boccia S, De Lauretis A, Gianfagna F, van Duijn CM, Ricciardi G. CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: a meta-analysis of the literature. Carcinogenesis 2007; 28: 101-106.
182. Cichoz-Lach H, Partycka J, Nesina I, Celinski K, Slomka M, Wojcierowski J. Alcohol dehydrogenase and aldehyde dehydrogenase gene polymorphism in alcohol liver cirrhosis and alcohol chronic pancreatitis among Polish individuals. Scand J Gastroenterol 2007; 42: 493-498.
183. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcoholmetabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006; 43: 352-361.
184. Vidal F, Lorenzo A, Auguet T, Olona M, Broch M, Gutierrez C, et al. Genetic polymorphisms of ADH2, ADH3, CYP4502E1 Dra-I and Pst-I, and ALDH2 in Spanish men: lack of association with alcoholism and alcoholic liver disease. J Hepatol 2004; 41: 744-750.
185. Lee HC, Lee HS, Jung SH, Yi SY, Jung HK, Yoon JH, et al. Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J Korean Med Sci 2001; 16: 745-750.
186. Sherman DI, Ward RJ, Warren-Perry M, Williams R, Peters TJ. Association of restriction fragment length polymorphism in alcohol dehydrogenase 2 gene with alcohol induced liver damage. BMJ 1993; 307: 1388-1390.
187. Yamauchi M, Maezawa Y, Mizuhara Y, Ohata M, Hirakawa J, Nakajima H, et al. Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients: a multivariate analysis. Hepatology 1995; 22: 1136-1142.
188. Burim RV, Canalle R, Martinelli Ade L, Takahashi CS. Polymorphisms in glutathione S-transferases GSTM1, GSTT1 and GSTP1 and cytochromes P450 CYP2E1 and CYP1A1 and susceptibility to cirrhosis or pancreatitis in alcoholics. Mutagenesis 2004; 19: 291-298.
189. Monzoni A, Masutti F, Saccoccio G, Bellentani S, Tiribelli C, Giacca M. Genetic determinants of ethanol-induced liver damage. Mol Med 2001; 7: 255-262.
190. Okamoto K, Murawaki Y, Yuasa And I, Kawasaki H. Effect of ALDH2 and CYP2E1 gene polymorphisms on drinking behavior and alcoholic liver disease in Japanese male workers. Alcohol Clin Exp Res 2001; 25: 19S-23S.
191. Pastor IJ, Laso FJ, Romero A, Gonzalez-Sarmiento R. -238 G>A polymorphism of tumor necrosis factor-α gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res 2005; 29: 1928-1931.
192. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26: 143-146.
193. Jarvelainen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33: 1148-1153.
194. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46: 540-545.
195. Takamatsu M, Yamauchi M, Maezawa Y, Saito S, Maeyama S, Uchikoshi T. Genetic polymorphisms of interleukin-1β in association with the development of alcoholic liver disease in Japanese patients. Am J Gastroenterol 2000; 95: 1305-1311.
196. Meiler C, Muhlbauer M, Johann M, Hartmann A, Schnabl B, Wodarz N, et al. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol 2005; 11: 6031-6037.
197. Chen WX, Xu GY, Yu CH, Wang P, Yu M, Xu P, et al. Correlation of polymorphism in the interleukin-1 receptor antagonist gene intron 2 with alcoholic liver disease. Hepatobiliary Pancreat Dis Int 2005; 4: 41-45.
198. Ladero JM, Martinez C, Garcia-Martin E, Fernandez-Arquero M, Lopez-Alonso G, de la Concha EG, et al. Polymorphisms of the glutathione S-transferases μ-1 (GSTM1) and ζ-1 (GSTT1) and the risk of advanced alcoholic liver disease. Scand J Gastroenterol 2005; 40: 348-353.
199. Degoul F, Sutton A, Mansouri A, Cepanec C, Degott C, Fromenty B, et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001; 120: 1468-1474.
200. Armstrong RN. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 1997; 10: 2-18.
201. Frenzer A, Butler WJ, Norton ID, Wilson JS, Apte MV, Pirola RC, et al. Polymorphism in alcohol-metabolizing enzymes, glutathione S-transferases and apolipoprotein E and susceptibility to alcoholinduced cirrhosis and chronic pancreatitis. J Gastroenterol Hepatol 2002; 17: 177-182.
202. Savolainen VT, Pjarinen J, Perola M, Penttila A, Karhunen PJ. Glutathione-S-transferase GST M1 "null" genotype and the risk of alcoholic liver disease. Alcohol Clin Exp Res 1996; 20: 1340-1345.
203. Kasahara H, Karasawa A, Ariyasu T, Thukahara T, Satou J, Ushijima S. Alcohol dementia and alcohol delirium in aged alcoholics. Psychiatry Clin Neurosci 1996; 50: 115-123.
204. Brun A, Andersson J. Frontal dysfunction and frontal cortical synapse loss in alcoholism the main cause of alcohol dementia? Dement Geriatr Cogn Disord 2001; 12: 289-294.
205. Tyas SL. Alcohol use and the risk of developing Alzheimer's disease. Alcohol Res Health 2001; 25: 299-306.
206. Landau AM, Kouassi E, Siegrist-Johnstone R, Desbarats J. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov Disord 2007; 22: 403-407.
207. Mattoo SK, Khurana H. Huntington's disease and alcohol abuse. Neurol India 1999; 47: 68-70.
208. Liappas I, Theotoka I, Kapaki E, Ilias I, Paraskevas GP, Soldatos CR. Neuropsychological assessment of cognitive function in chronic alcohol-dependent patients and patients with Alzheimer's disease. In Vivo 2007; 21: 1115-1118.
209. Graves AB, van Duijn CM, Chandra V, Fratiglioni L, Heyman A, Jorm AF, et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991; 20 (Suppl 2): S48-57.
210. Cervilla JA, Prince M, Mann A. Smoking, drinking, and incident cognitive impairment: a cohort community based study included in the Gospel Oak project. J Neurol Neurosurg Psychiatry 2000; 68: 622-626.
211. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Jr., Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155: 732-738. (Pubitemid 34297653)
212. Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, et al. Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996; 47: 636-643.
213. Hernan MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease. Ann Neurol 2003; 54: 170-175. (Pubitemid 36909616)
214. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000; 55: 1350-1358.
215. Buervenich S, Sydow O, Carmine A, Zhang Z, Anvret M, Olson L. Alcohol dehydrogenase alleles in Parkinson's disease. Mov Disord 2000; 15: 813-818.
216. Mullin PJ, Kershaw PW, Bolt JM. Choreoathetotic movement disorder in alcoholism. Br Med J 1970; 4: 278-281.
217. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991; 48: 800-804.
218. Lutz EG. Neuroleptic-induced akathisia and dystonia triggered by alcohol. JAMA 1976; 236: 2422-2423.
219. Tan EK, Nagamitsu S, Matsuura T, Khajavi M, Jankovic J, Ondo W, et al. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett 2001; 305: 70-72. (Pubitemid 32436477)
220. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 2009; 36: S15-23.
221. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75: 34-56.
222. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006; 111: 855-876. (Pubitemid 44118437)
223. Keung WM. Anti-dipsotropic isoflavones: the potential therapeutic agents for alcohol dependence. Med Res Rev 2003; 23: 669-696.
224. Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997; 53: 1038-1053.
225. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008; 32: 1105-1110.
226. Scott LJ, Figgitt DP, Keam SJ, Waugh J. Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. CNS Drugs 2005; 19: 445-464. (Pubitemid 41130680)
227. Boothby LA, Doering PL. Acamprosate for the treatment of alcohol dependence. Clin Ther 2005; 27: 695-714.
228. Brewer C. Recent developments in disulfiram treatment. Alcohol Alcohol 1993; 28: 383-395.
229. Petersen EN. The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 7-13.
230. Glauser TA, Nelson AN, Zembower DE, Lipsky JJ, Weinshilboum RM. Diethyldithiocarbamate S-methylation: evidence for catalysis by human liver thiol methyltransferase and thiopurine methyltransferase. J Pharmacol Exp Ther 1993; 266: 23-32.
231. Madan A, Parkinson A, Faiman MD. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram. Drug Metab Dispos 1995; 23: 1153-1162.
232. Madan A, Parkinson A, Faiman MD. Identification of the human P450 enzymes responsible for the sulfoxidation and thionooxidation of diethyldithiocarbamate methyl ester: role of P450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22: 1212-1219. (Pubitemid 28443143)
233. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 15-26.
234. Pike MG, Martin YN, Mays DC, Benson LM, Naylor S, Lipsky JJ. Roles of FMO and CYP450 in the metabolism in human liver microsomes of S-methyl-N,N- diethyldithiocarbamate, a disulfiram metabolite. Alcohol Clin Exp Res 1999; 23: 1173-1179.
235. Soyka M, Rosner S. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review. Curr Drug Abuse Rev 2008; 1: 280-291.
236. Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med 2008; 359: 715-721.
237. Weinrieb RM, O'Brien CP. Naltrexone in the treatment of alcoholism. Annu Rev Med 1997; 48: 477-487.
238. Wall ME, Brine DR, Perez-Reyes M. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 1981; 9: 369-375. (Pubitemid 11057598)
239. Day CP. Apoptosis in alcoholic hepatitis: a novel therapeutic target? J Hepatol 2001; 34: 330-333.
240. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001; 34: 248-253. (Pubitemid 32176446)
241. Wolff GS, Chiang PJ, Smith SM, Romero R, Armant DR. Epidermal growth factor-like growth factors prevent apoptosis of alcohol-exposed human placental cytotrophoblast cells. Biol Reprod 2007; 77: 53-60. (Pubitemid 46986396)
242. Brebner K, Childress AR, Roberts DC. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 2002; 37: 478-484.
243. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: 487-495.
244. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119: 276 e13-8.
245. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-1922.
246. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991; 41: 574-595.
247. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-189.
248. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879-885.
249. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996; 24: 602-609.
250. Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P, et al. The polymorphic cytochrome P4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22: 269-274.
251. Latini G, Verrotti A, Manco R, Scardapane A, Del Vecchio A, Chiarelli F. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem 2008; 8: 10-23.
252. Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs 2007; 67: 2231-2256.
253. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41 (Suppl 1): S61-5.
254. Sachdeo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998; 34: 335-346.
255. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752-773.
256. Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother 2008; 42: 1475-1480.
257. Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2009; 2: 135-142.
258. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-1685.
259. Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction 2006; 101: 1561-1568.
260. De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 2008; 34: 460-463.
261. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-1651.
262. Miranda R, Jr., MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008; 32: 489-497.
263. Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 2008; 32: 1251-1259.
264. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996; 31: 29-46.
265. Bourgeois BF. Pharmacokinetics and metabolism of topiramate. Drugs Today (Barc) 1999; 35: 43-48.
266. Schneiderman JH. Topiramate: pharmacokinetics and pharmacodynamics. Can J Neurol Sci 1998; 25: S3-5.
267. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763-780.
268. Britzi M, Perucca E, Soback S, Levy RH, Fattore C, Crema F, et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 2005; 46: 378-384.
269. Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002; 43: 691-696.
270. Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK, et al. Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. Neuropsychopharmacology 2006; 31: 1574-1582.
271. Flatscher-Bader T, van der Brug M, Hwang JW, Gochee PA, Matsumoto I, Niwa S, et al. Alcohol-responsive genes in the frontal cortex and nucleus accumbens of human alcoholics. J Neurochem 2005; 93: 359-370.
272. Iwamoto K, Bundo M, Yamamoto M, Ozawa H, Saito T, Kato T. Decreased expression of NEFH and PCP4/PEP19 in the prefrontal cortex of alcoholics. Neurosci Res 2004; 49: 379-385.
273. Liu J, Lewohl JM, Dodd PR, Randall PK, Harris RA, Mayfield RD. Gene expression profiling of individual cases reveals consistent transcriptional changes in alcoholic human brain. J Neurochem 2004; 90: 1050-1058.
274. Hassan S, Duong B, Kim KS, Miles MF. Pharmacogenomic analysis of mechanisms mediating ethanol regulation of dopamine beta-hydroxylase. J Biol Chem 2003; 278: 38860-38869.
275. Seth D, Leo MA, McGuinness PH, Lieber CS, Brennan Y, Williams R, et al. Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am J Pathol 2003; 163: 2303-2317.
276. Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, Goria O, et al. Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol 2009; 15: 300-309.
277. Lewohl JM, Wang L, Miles MF, Zhang L, Dodd PR, Harris RA. Gene expression in human alcoholism: microarray analysis of frontal cortex. Alcohol Clin Exp Res 2000; 24: 1873-1882.
278. Thibault C, Lai C, Wilke N, Duong B, Olive MF, Rahman S, et al. Expression profiling of neural cells reveals specific patterns of ethanol-responsive gene expression. Mol Pharmacol 2000; 58: 1593-1600.
279. Chen YJ, Chen C, Wu DC, Lee CH, Wu CI, Lee JM, et al. Interactive effects of lifetime alcohol consumption and alcohol and aldehyde dehydrogenase polymorphisms on esophageal cancer risks. Int J Cancer 2006; 119: 2827-2831.
280. Minegishi Y, Tsukino H, Muto M, Goto K, Gemma A, Tsugane S, et al. Susceptibility to lung cancer and genetic polymorphisms in the alcohol metabolite-related enzymes alcohol dehydrogenase 3, aldehyde dehydrogenase 2, and cytochrome P450 2E1 in the Japanese population. Cancer 2007; 110: 353-362. (Pubitemid 47121896)
281. Zheng T, Holford TR, Zahm SH, Owens PH, Boyle P, Zhang Y, et al. Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk. Br J Cancer 2003; 88: 58-62. (Pubitemid 36241219)
282. Gao CM, Takezaki T, Wu JZ, Chen MB, Liu YT, Ding JH, et al. CYP2E1 Rsa I polymorphism impacts on risk of colorectal cancer association with smoking and alcohol drinking. World J Gastroenterol 2007; 13: 5725-5730.
283. Wong NA, Rae F, Bathgate A, Smith CA, Harrison DJ. Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population. Toxicol Lett 2000; 115: 17-22. (Pubitemid 30417451)
284. Valenti L, De Feo T, Fracanzani AL, Fatta E, Salvagnini M, Arico S, et al. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol Alcohol 2004; 39: 276-280. (Pubitemid 38968080)
285. Hernandez-Nazara ZH, Ruiz-Madrigal B, Martinez-Lopez E, Roman S, Panduro A. Association of the epsilon 2 allele of APOE gene to hypertriglyceridemia and to early-onset alcoholic cirrhosis. Alcohol Clin Exp Res 2008; 32: 559-566.
286. Ropero Gradilla P, Villegas Martinez A, Fernandez Arquero M, Garcia-Agundez JA, Gonzalez Fernandez FA, Benitez Rodriguez J, et al. C282Y and H63D mutations of HFE gene in patients with advanced alcoholic liver disease. Rev Esp Enferm Dig 2001; 93: 156-163.
287. Rossit AR, Cabral IR, Hackel C, da Silva R, Froes ND, Abdel- Rahman SZ. Polymorphisms in the DNA repair gene XRCC1 and susceptibility to alcoholic liver cirrhosis in older Southeastern Brazilians. Cancer Lett 2002; 180: 173-182.
288. Fowler CJ. "The tools of the trade" - an overview of the pharmacology of the endocannabinoid system. Curr Pharm Des 2008; 14(23): 2254-2265.
289. Pal M, Angaru S, Kodimuthali A, Dhingra N. Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management. Curr Pharm Des 2009; 15(9): 1008-1026.
290. Schalekamp T, de Boer A. Pharmacogenetics of Oral Anticoagulant Therapy. Curr Pharm Des 2009.